NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Published in Chemical Science • Apr 4, 2014
Authors:,,
Robert Trondl
Petra Heffeter
Christian R. Kowol
Abstract
NKP-1339 is the first-in-class ruthenium-based anticancer drug in clinical development against solid cancer and has recently been studied successfully in a phase I clinical trial. Ruthenium compounds such as KP1019 (indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]) and NKP-1339 (the so...